Cost Effectiveness of Erlotinib Versus Gemcitabine/Carboplatin in First-Line Therapy of Advanced EGFR-Mutations Positive Non-Small-Cell Lung Cancer
May 1, 2016, 00:00
10.1016/j.jval.2016.03.1603
https://www.valueinhealthjournal.com/article/S1098-3015(16)01671-5/fulltext
Title :
Cost Effectiveness of Erlotinib Versus Gemcitabine/Carboplatin in First-Line Therapy of Advanced EGFR-Mutations Positive Non-Small-Cell Lung Cancer
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)01671-5&doi=10.1016/j.jval.2016.03.1603
First page :
A152
Section Title :
Cancer - Cost Studies
Open access? :
No
Section Order :
324